Silvant Capital Management’s Tandem Diabetes Care TNDM Stock Holding History

Silvant Capital Management’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,011	Closed	-$288K	–	361
2022 Q3	$288K	Hold	6,011	–	–	0.02%	172
2022 Q2	$356K	Hold	6,011	–	–	0.09%	113
2022 Q1	$699K	Hold	6,011	–	–	0.13%	104
2021 Q4	$905K	Sell	6,011 -1,296	-18%	-$175K	0.15%	97
2021 Q3	$872K	Hold	7,307	–	–	0.16%	99
2021 Q2	$712K	Hold	7,307	–	–	0.11%	110
2021 Q1	$645K	Hold	7,307	–	–	0.11%	112
2020 Q4	$699K	Hold	7,307	–	–	0.12%	110
2020 Q3	$829K	Hold	7,307	–	–	0.16%	97
2020 Q2	$723K	Hold	7,307	–	–	0.13%	99
2020 Q1	$470K	Hold	7,307	–	–	0.1%	106
2019 Q4	$436K	Hold	7,307	–	–	0.08%	119
2019 Q3	$431K	Hold	7,307	–	–	0.09%	116
2019 Q2	$471K	Hold	7,307	–	–	0.08%	118
2019 Q1	$464K	Hold	7,307	–	–	0.08%	120
2018 Q4	$277K	Buy	+7,307	New	+$258K	0.06%	154

Other funds holding TNDM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Silvant Capital Management's TNDM Position: Q4 2022 in Review

Silvant Capital Management sold out of Tandem Diabetes Care (TNDM) in Q4 2022, closing a stake of 6,011 shares — an estimated $288K sold.

Silvant Capital Management first reported a position in TNDM in Q4 2018 and held it in 16 quarters. The position peaked at $905K in Q4 2021. 295 funds tracked by Wall St. Rank hold TNDM as of Q4 2022.

Silvant Capital Management reported no remaining Tandem Diabetes Care position as of Q4 2022 after selling out during the quarter.
Silvant Capital Management sold 6,011 Tandem Diabetes Care shares in Q4 2022, an estimated $288K.
Silvant Capital Management first reported a position in Tandem Diabetes Care in Q4 2018 and held it in 16 quarters.
Silvant Capital Management's Tandem Diabetes Care position peaked at $905K in Q4 2021.
295 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2022.

Based on Silvant Capital Management's 13F filing for Q4 2022, filed 23 Jan 2023.